Physician profile
John E Short
NPI 1700935277
$3,866.94
in general payments reported to CMS, 2019-2025
28 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,043 · 2022: $1,203 · 2023: $674 · 2024: $569 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $807.58 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $413.98 | 2022-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $374.31 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.99 | 2022-2025 | Jardiance |
| Amgen INC. | $298.45 | 2021-2024 | Evenity, Prolia |
| Lilly USA, LLC | $282.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $254.93 | 2021-2024 | |
| Radius Health, INC. | $172.73 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $153.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $137.60 | 2021 | |
| Insulet Corporation | $92.47 | 2022-2023 | Omnipod |
| Esperion Therapeutics, INC. | $73.88 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $71.98 | 2021-2022 | |
| Abbott Laboratories | $68.52 | 2021-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $57.53 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.16 | 2021-2022 | |
| Dexcom, INC. | $35.33 | 2021 | |
| Pfizer INC. | $30.10 | 2025 | |
| Genentech USA, INC. | $26.96 | 2021 | |
| Medtronic, INC. | $22.75 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $21.47 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.13 | 2021 | |
| Tandem Diabetes Care, INC. | $17.60 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Avion Pharmaceuticals | $15.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2021 | |
| Allergan, INC. | $13.17 | 2021 | |
| Recordati_rare_diseases_inc. | $12.80 | 2023 | Isturisa |
| Beta Bionics, INC. | $11.93 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.